What are the main reasons Amgen is presenting non-GAAP financial measures?

Amgen presents non-GAAP financial measures to provide supplemental information that they believe enhances comparability across reporting periods. These adjustments aim to exclude the impact of stock option expensing, amortization of intangible assets from acquisitions, and other one-time or non-recurring events, allowing investors to better assess the company's core operational performance and trends.

What specific expenses are being excluded in the non-GAAP measures for the third quarter of 2006?

For the third quarter of 2006, Amgen's non-GAAP adjustments primarily exclude the impact of expensing stock options under SFAS No. 123R, amortization of intangible assets related to the Abgenix acquisition (XenoMouse technology), and amortization and impairment of intangible assets from the Immunex acquisition (including Enbrel-related assets). They also exclude certain acquisition-related employee retention compensation and an Abgenix in-process R&D write-off.

How do the non-GAAP adjustments for 2005 differ from those in 2006?

While both periods involve adjustments for stock option expensing and acquisition-related intangible amortization, the specific one-time items differ. For 2005, adjustments included a write-off of a manufacturing asset, legal settlements, a gain from terminating a manufacturing agreement with Genentech, and expenses related to convertible notes. In contrast, 2006 focused more on acquisition-related impacts like stock option expensing, intangible amortization from recent acquisitions (Abgenix, Tularik, Immunex), and related employee retention costs and write-offs.

Why is Amgen providing adjusted earnings per share that include stock option expensing?

Amgen is providing adjusted earnings per share that include the impact of expensing stock options as a convenience to investors. They acknowledge that the treatment of stock option expensing can vary across industries and reporting periods, and by presenting this figure alongside their primary non-GAAP measures, they allow investors to compare performance both with and without this specific accounting impact.

AMGN 8-K: Earnings & Results

Summary

This 8-K filing from Amgen Inc. on October 23, 2006, primarily announces the company's unaudited financial results for the third quarter and the first nine months of 2006. A significant focus of the report is the presentation of non-GAAP financial measures, which exclude certain expenses to provide what the company believes is a clearer view of ongoing operational performance and comparability across periods. Key adjustments include the expensing of stock options under SFAS No. 123R, amortization of intangible assets from significant acquisitions (Abgenix, Tularik, Immunex), and other one-time or non-recurring items such as acquisition-related expenses, impairments, and legal settlements. Investors should pay close attention to these adjustments to understand the underlying trends in Amgen's revenue and profitability, particularly as the company navigates the impact of these significant accounting changes and strategic acquisitions.

Key Highlights

1Amgen reported its unaudited financial results for the third quarter and first nine months of 2006.
2The company presented non-GAAP financial measures, excluding certain expenses to enhance comparability.
3Adjustments for stock option expensing (SFAS No. 123R) were a significant focus for both 2006 and 2005 periods.
4Amortization of intangible assets related to acquisitions (Abgenix, Tularik, Immunex) was a key exclusion in non-GAAP reporting.
5Acquisition-related expenses, including Abgenix IPR&D write-off and employee retention compensation, were also adjusted.
6For the prior year (2005), adjustments included a manufacturing asset write-off, legal settlements, and gains/losses from contract terminations and debt instruments.
7The company believes these non-GAAP measures provide useful supplementary information for investors.

AMGEN INC 8-K Report, Financial Results (Oct 23, 2006)

Summary

Key Highlights

Frequently Asked Questions